Detection of Minimal Residual Disease Using Exosomal miRNA Distant Metastasis Markers

Recruiting now

Conditions studied: Gastric Cancer

In brief

Gastric cancer (GC) is a leading cause of cancer-related death worldwide. Even in patients undergoing curative surgery for non-metastatic disease, postoperative recurrence frequently occurs due to undetected minimal residual disease (MRD). This study aims to establish a highly sensitive and specific liquid biopsy assay using exosomal microRNAs (exo-miRNAs) to detect MRD and predict distant metastasis before clinical recurrence.

Key facts

Study ID

NCT07243015

Run by

City of Hope Medical Center

People needed

500

Starts

2025-01-15

Expected to finish

2028-06-18

Last updated by the study team

2026-07-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed gastric adenocarcinoma.
• Underwent curative-intent resection (R0).
• Availability of pre- and postoperative plasma samples.
• Documented clinical follow-up data (recurrence/metastasis status).
• Provided written informed consent.

You may not qualify if…

• Insufficient plasma volume or RNA quality for exosomal extraction.
• Presence of synchronous or metachronous malignancies.
• Received neoadjuvant chemotherapy without postoperative follow-up.
• Lack of consent or incomplete clinicopathologic data.

Where it is running

• City of Hope Medical Center — Duarte, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.